AbbVie Inc. $ABBV is Clarity Financial LLC’s 5th Largest Position

Clarity Financial LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 8.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 198,762 shares of the company’s stock after acquiring an additional 16,086 shares during the period. AbbVie comprises approximately 4.2% of Clarity Financial LLC’s portfolio, making the stock its 5th biggest holding. Clarity Financial LLC’s holdings in AbbVie were worth $50,016,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Ranch Capital Advisors Inc. increased its position in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after purchasing an additional 4,017 shares during the period. Calamos Advisors LLC lifted its position in shares of AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock worth $106,543,000 after purchasing an additional 15,458 shares during the period. Wedge Capital Management L L P NC boosted its stake in shares of AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after purchasing an additional 9,380 shares in the last quarter. Axecap Investments LLC boosted its stake in shares of AbbVie by 713.2% during the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock valued at $3,729,000 after purchasing an additional 14,313 shares in the last quarter. Finally, Legacy Edge Advisors LLC purchased a new position in shares of AbbVie during the fourth quarter valued at about $1,265,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Price Performance

NYSE:ABBV opened at $251.20 on Friday. The firm has a market capitalization of $443.82 billion, a P/E ratio of 70.96, a PEG ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The company’s 50-day simple moving average is $244.51 and its 200 day simple moving average is $225.96.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong post-Humira growth: AbbVie reported first-quarter 2026 revenue of $15.002 billion, up 12.4% year over year on a reported basis and 10.3% operationally. Adjusted diluted EPS of $2.65 exceeded internal expectations despite a $0.41-per-share headwind from acquired in-process research and development costs, supporting confidence in the company’s ability to replace Humira-related sales. Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
• Positive Sentiment: Analyst support strengthened: Wolfe Research upgraded AbbVie, citing the company’s pipeline strength and valuation. BNP Paribas Exane also indicated that the stock could rise, adding to the bullish research tone. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation AbbVie Stock Price Expected to Rise, BNP Paribas Exane Analyst Says
• Positive Sentiment: Commercial and pipeline catalysts: AbbVie’s Botox filing and Canada’s reimbursement recommendation for UBRELVY in adult migraine treatment could expand revenue opportunities in aesthetics and neuroscience. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Neutral Sentiment: Updates on venetoclax in high-risk myelodysplastic syndromes and a completed Phase 3 Botox jawline study provide potential longer-term catalysts, but their financial impact depends on additional data, regulatory decisions, and commercialization. AbbVie’s Venetoclax Combo in High-Risk MDS
• Negative Sentiment: Erste Group Bank lowered its AbbVie earnings estimates, highlighting a counterpoint to the positive upgrades and potentially limiting near-term upside. Erste Group Bank Lowers Earnings Estimates for AbbVie

Analysts Set New Price Targets

ABBV has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and issued a $298.00 price target on shares of AbbVie in a research note on Tuesday, June 23rd. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Wells Fargo & Company increased their target price on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, July 10th. BNP Paribas Exane raised their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Morgan Stanley restated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.50.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.